Informational letter to healthcare professionals on the need to monitor metabolic processes, the increased risk of extrapyramidal symptoms and somnolence in patients taking medicinal products containing the active substance quetiapine

20.12.2023 2252 views

Інформаційний лист-звернення до фахівців системи охорони здоров’я щодо необхідності здійснення моніторингу метаболічних процесів, підвищеного ризику екстрапірамідних симптомів і сонливості у пацієнтів, які застосовують лікарські засоби з діючою речовиною кветіапінPDF · 525 КБ

Завантажити

Informational letter to healthcare professionals on the need to monitor metabolic processes, the increased risk of extrapyramidal symptoms and somnolence in patients taking medicinal products containing the active substance quetiapine

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Informational letter to healthcare professionals on the need to monitor metabolic processes, the increased risk of extrapyramidal symptoms and somnolence in patients taking medicinal products containing the active substance quetiapine

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration